voglibose

Small moleculeexperimental

Voglibose is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus. — Wikipedia

Clinical trial activity

18 trials · 16 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
6
Phase 3
6
Phase 4
8

Earliest trial started Apr 1, 2005 (NCT00212017)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O
Mol. weight
267.28 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-c-(hydroxymethyl)-d-epi-inositol
  • a-71100
  • a-71100
  • ao 128
  • ao-128
  • ao-128
  • ao-128
  • ao-128
  • basen
  • basen
  • basen
  • basen
  • epi-inositol, 2,3-dideoxy-2-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-4-c-(hydroxymethyl)-
  • glustat
  • glustat
  • glustat
  • n-(1,3-dihydroxy-2-propyl)valiolamine
  • voglibose
  • voglibose
  • voglibose
  • voglibose
  • voglibose
  • voglibose
  • voglibose
  • voglibose
  • voglibose
  • voglistat

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05688332Phase 3Aug 31, 2023University of Zambia, University Teaching Hospital, Lusaka, Zambia
NCT02954692Phase 4Nov 30, 2016Sanofi
NCT02730377Phase 4Mar 28, 2016Novo Nordisk
NCT02049814Phase 4Jun 1, 2014Takeda
NCT02097342Phase 4Dec 1, 2013Postgraduate Institute of Medical Education and Research
NCT01309698Phase 4Feb 1, 2011Novartis
NCT02287402Phase 4Mar 1, 2010Takeda
NCT00970528Phase 4Nov 1, 2009Bayer
NCT00837577Phase 3Feb 5, 2009Merck
NCT00724542N/AJul 1, 2008Government of China, Peking University, Takeda
NCT00654381Phase 3Apr 1, 2008Boehringer Ingelheim
NCT00663884Phase 4Feb 1, 2008Catholic University of Korea, JW Pharmaceutical
NCT01263509Phase 2/Phase 3 (Phase 3)Jun 1, 2007Kawasaki Medical University, Takeda
NCT01263496Phase 2May 1, 2007Kawasaki Medical University, Takeda
NCT01263483Phase 2/Phase 3 (Phase 3)Jan 1, 2007Kawasaki Medical University, Takeda
NCT01263470Phase 2Jan 1, 2007Kawasaki Medical University, Takeda
NCT00411554Phase 3Jan 1, 2007Merck
NCT00212017N/AApr 1, 2005National Cerebral and Cardiovascular Center
Showing 18 of 18 trials
Page 1 / 1

Organizations

Research & Development (16)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
TakedaFor profit7642007
Kawasaki Medical UniversityAcademic/Hospital4022007
MerckFor profit2212007
BayerFor profit1112009
Boehringer IngelheimFor profit1112008
Catholic University of KoreaAcademic/Hospital1012008
Government of ChinaGovernment1112008
JW PharmaceuticalFor profit1112008
National Cerebral and Cardiovascular CenterGovernment1112005
NovartisFor profit1112011
Novo NordiskFor profit1112016
Peking UniversityAcademic/Hospital1012008
Postgraduate Institute of Medical Education and ResearchAcademic/Hospital1112013
SanofiFor profit1112016
University of ZambiaAcademic/Hospital1112023
University Teaching Hospital, Lusaka, ZambiaAcademic/Hospital1012023
16 organizations
Page 1 / 1